GlassScriptPhysician profile
Ryan Kian Hakimi
NPI 1780858753
$2,445.65
in general payments reported to CMS, 2019-2025
14 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Neurocritical Care provider received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $285 · 2021: $18.78 · 2022: $182 · 2023: $494 · 2024: $629 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irras USA, INC. | $575.71 | 2019-2024 | |
| Amgen INC. | $384.41 | 2024-2025 | Uplizna |
| Horizon Therapeutics Plc | $333.37 | 2022-2023 | Uplizna |
| Cumberland Pharmaceuticals, INC. | $237.09 | 2022-2023 | Caldolor |
| Ucb, INC. | $235.89 | 2023-2024 | Briviact |
| Ceribell, INC. | $160.00 | 2020 | |
| Portola Pharmaceuticals, LLC | $125.00 | 2020 | |
| Chiesi USA, INC. | $109.75 | 2025 | Cleviprex |
| Immedica Pharma US, INC. | $108.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $106.50 | 2024 | Andexxa |
| Novartis Pharmaceuticals Corporation | $19.88 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.78 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.61 | 2019 | |
| Neural Analytics, INC. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hakimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.